Infusion of unlicensed umbilical cord blood cells for treatment
Official title: Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
Run by Masonic Cancer Center, University of Minnesota · NCT01451502 · Data updated 2026-11-12
This study is testing whether infusing unlicensed umbilical cord blood cells can help people with lymphatic diseases or blood cancers recover after their treatment.
Quick facts
| Study type | Interventional |
|---|---|
| Sex | All |
| Enrollment | 250 (estimated) |
| Sponsor | Masonic Cancer Center, University of Minnesota Academic / other |
| Locations | 1 site (Minneapolis, Minnesota) |
| Status | Recruiting |
| Started | October 20, 2011 |
| Main results expected | January 2027 |
| Study ends | February 2028 |
| Registry record updated | October 6, 2026 |
| Trial ID | NCT01451502 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients with specific diagnoses that require UCB for hematopoietic stem cell therapy and who meet the eligibility criteria set by the study.
✕Probably not a fit
Patients who do not have an unlicensed UCB unit that meets the required criteria or those without an appropriate diagnosis may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study involves the infusion of unlicensed umbilical cord blood (UCB) units into patients with lymphatic diseases or hematopoietic malignancies. Patients will receive pre-infusion hydration and medications to manage potential side effects. The study aims to explore the use of UCB as a source of hematopoietic stem cells for reconstitution after conditioning treatments, following specific protocols approved by the institutional review board at the University of Minnesota.
Why it matters
Potential benefit: If successful, this approach could provide a new source of stem cells for patients requiring hematopoietic reconstitution, potentially improving treatment outcomes.
How similar studies have gone: While the use of licensed UCB units has been well-studied, the infusion of unlicensed UCB units is a novel approach that has not been extensively tested in clinical settings.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: To be eligible for an unlicensed umbilical cord blood (UCB) unit, the subject must meet each of the eligibility criteria listed below: * Subjects with any diagnosis for which there is an institutional review board (IRB) approved treatment protocol that requires UCB as a source of hematopoietic stem cells for lympho-hematopoietic reconstitution after myeloablative or non myeloablative conditioning. * Subject (or parent/guardian) must provide written informed consent for the use of unlicensed UCB units with co-enrollment onto a University of Minnesota IRB-approved clinical trial that details the disease specific treatment plan that prescribes the use of UCB as source of cells * Subject has an unlicensed UCB unit that meets required cell dose and HLA matching criteria (as defined in the primary treatment protocol) that is considered negative for tested blood-borne pathogens and also lack an 'equivalent', licensed UCB unit from a University of Minnesota approved Cord Blood Bank Exclusion Criteria: * Exclusion criteria are specified in the treatment protocol according to indication.
Where it's running
-
Masonic Cancer Center, University of Minnesota
Minneapolis, Minnesota, United States Recruiting
Study contacts
- Principal investigator: Alex Hoover, MD, MSc — Masonic Cancer Center, University of Minnesota
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Understanding lymphatic anomalies over time
This study is looking to see how lymphatic anomalies change over time in people who have them and their family members, to better understand these conditions and improve future treatments.
-
See if virtual informed consent methods help people decide to join cancer research
This trial tests whether virtual human communicators and different consent messages can influence cancer patients’ understanding and willingness to participate in research.
-
AI-powered supportive care chatbot for young adult cancer survivors
A chatbot driven by artificial intelligence is tested to help young adult cancer survivors manage symptoms and care needs after treatment.
-
Telehealth pharmacist-led opioid education for cancer patients
This pilot tests a telehealth group education session led by a palliative care pharmacist to help adults with cancer use opioids more safely and effectively.
-
Mindfulness program to help with symptoms in chronic graft-versus-host disease
A mindfulness-based program is being tested to see if it can reduce patient-reported symptoms for adults with chronic graft-versus-host disease after a stem cell transplant.
-
Non-invasive brain stimulation to help chemotherapy-induced nerve problems in cancer survivors
This trial tests whether a gentle brain stimulation method (tDCS) can help reduce numbness, tingling, and pain from CIPN in cancer survivors who are not currently in treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.